| Name | Title | Contact Details |
|---|
PAT Services is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As an integrated, not-for-profit organization, CentraCare is working to improve the lives and wellbeing of those living in Central Minnesota. CentraCare provides care through hospitals located in St. Cloud, Long Prairie, Melrose, Monticello, Paynesville and Sauk Centre with more than 25 clinics and specialty centers throughout the region. Additionally, Carris Health, a wholly-owned subsidiary of CentraCare, is comprised of Rice Memorial Hospital in Willmar, Redwood Hospital in Redwood Falls and seven clinics in the Southwest and West Central region of the state. CentraCare – St. Cloud Hospital has been a Magnet-designated hospital since 2004 and repeatedly receives national recognition for its outstanding quality measures. CentraCare provides comprehensive primary through tertiary care, CentraCare also operates numerous specialty services, including the CentraCare Heart & Vascular Center, Coborn Cancer Center and the CentraCare Kidney Program. CentraCare serves all who seek care with compassion, dignity and respect, while seeking to enhance individual and community health. Mission: CentraCare Health works to improve the health of every patient, every day. Vision: CentraCare Health will be the leader in Minnesota for quality, safety, service and value. Core Values: •Patient Centered: Serving patients above all. •Integrity: Adhering to honest and ethical practices. •Collaboration: Working jointly with others to improve health and health care. •Compassion: Serving all who seek our care with kindness, dignity, and respect. •Stewardship: Ensuring responsible use of all resources to best serve our communities.
DOCTORS HOSPITAL WEST COVINA is a West Covina, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
CHAD Therapeutics, Inc. (CHAD) was established to develop, produce and market respiratory care devices designed to improve the efficiency of oxygen delivery systems for both home and hospital treatment of patients who require supplemental oxygen.